Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis

Summary

Platelets are suggested to play a crucial role in cancer progression and the prothrombotic state of cancer patients. Here, we aimed to examine the activation status of platelets in cancer patients and investigate their association with risk of death and occurrence of venous thromboembolism (VTE) in a prospective observational cohort study. We measured platelet surface P-selectin, activated glycoprotein (GP) IIb/IIIa and monocyte-platelet aggregate (MPA) formation in vivo and platelet response to ex vivo stimulation with agonists of protease-activated receptor (PAR) −1, −4, and GPVI, by whole blood flow cytometry, before beginning of chemotherapy and repeatedly during the first six months thereafter (total number of samples analysed: 230). Endpoints of the study were occurrence of death or VTE during a two-year follow-up, respectively. Of 62 patients (median age [interquartile range, IQR]: 63 [54–70] years, 48 % female), 32 (51.6 %) died and nine (14.5 %) developed VTE. Association with a higher risk of death was found for lower platelet surface expression of P-selectin and activated GPIIb/IIIa in vivo and in response to PAR-1, −4 and GPVI activation, but not for MPA formation. Furthermore, reduced platelet responsiveness to PAR-1 and GPVI agonists was associated with higher risk of VTE (hazard ratio per decile increase of percentage P-selectin positive platelets: 0.73 [0.56–0.92, p=0.007] and 0.77 [0.59–0.98, p=0.034], respectively). In conclusion, cancer patients with a poor prognosis showed decreased platelet reactivity, presumably as a consequence of continuous activation. Our data suggest that decreased platelet reactivity is associated with increased mortality and VTE in cancer.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Platelets - thrombosis - monocyte-platelet aggregates - cancer - mortality

^# These authors share senior authorship.

• References

• 1 Nash GF, Turner LF, Scully MF. et al Platelets and cancer. Lancet Oncol 2002; 03: 425-430.
• 2 Karpatkin S, Pearlstein E, Salk PL. et al Role of platelets in tumor cell meta-stases. Ann NY Acad Sci 1981; 370: 101-118.
• 3 Mitrugno A, Williams D, Kerrigan SW. et al A novel and essential role for FcγRIIa in cancer cell-induced platelet activation. Blood 2014; 123: 249-260.
• 4 Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis. Hämostaseologie 2014; 34: 54-62.
• 5 Khorana AA, Francis CW, Culakova E. et al Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104: 2822-2829.
• 6 Buergy D, Wenz F, Groden C. et al Tumor-platelet interaction in solid tumors. Int J Cancer 2012; 130: 2747-2760.
• 7 Stone RL, Nick AM, McNeish IA. et al Paraneoplastic Thrombocytosis in Ovarian Cancer. N Engl J Med 2012; 366: 610-618.
• 8 Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123-134.
• 9 Rothwell PM, Price JF, Fowkes FGR. et al Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-1612.
• 10 Rothwell PM, Wilson M, Price JF. et al Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-1601.
• 11 Königsbrügge O, Lötsch F, Reitter E-M. et al Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism. J Thromb Haemost 2013; 11: 1993-2000.
• 12 Dickmann B, Ahlbrecht J, Ay C. et al Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013; 98: 1309-1314.
• 13 Ahlbrecht J, Dickmann B, Ay C. et al Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2012; 30: 3870-3875.
• 14 Simanek R, Vormittag R, Ay C. et al High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 08: 114-120.
• 15 Riedl J, Kaider A, Reitter E-M. et al Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost 2014; 111: 670-678.
• 16 Ferroni P, Guadagni F, Riondino S. et al Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. Haematologica 2014; 99: 1638-1644.
• 17 Ay C, Simanek R, Vormittag R. et al High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112: 2703-2708.
• 18 Ay C, Vormittag R, Dunkler D. et al D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27: 4124-4129.
• 19 Gremmel T, Koppensteiner R, Panzer S. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy. PLoS ONE 2015; 10: e0129666.
• 20 Gremmel T, Eslam RB, Koppensteiner R. et al Prasugrel reduces agonists’ inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. Cardiovasc Ther 2013; 31: e40-45.
• 21 Dymicka-Piekarska V, Matowicka-Karna J, Osada J. et al Changes in platelet CD 62P expression and soluble P-selectin concentration in surgically treated colorectal carcinoma. Adv Med Sci 2006; 51: 304-308.
• 22 Gong L, Cai Y, Zhou X. et al Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1. Pathol Oncol Res 2012; 18: 989-996.
• 23 Mantur M, Kemona H, Kozłowski R. et al Effect of tumor stage and nephrec-tomy on CD62P expression and sP-selectin concentration in renal cancer. Neo-plasma 2003; 50: 262-265.
• 24 Boneu B, Bugat R, Boneu A. et al Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathy. Eur J Cancer Clin Oncol 1984; 20: 899-903.
• 25 Italiano Jr JE, Richardson JL, Patel-Hett S. et al Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-1233.
• 26 Gunsilius E, Petzer A, Stockhammer G. et al Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000; 58: 169-174.
• 27 Starlinger P, Moll HP, Assinger A. et al Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. J Thromb Haemost 2010; 08: 1809-1819.
• 28 Posch F, Thaler J, Zlabinger G-J. et al Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS). Clin Cancer Res 2016; 22: 200-206.
• 29 Riedl J, Hell L, Kaider A. et al Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets 2015; 1-6.
• 30 Jurk K, Jahn U-R, Van Aken H. et al Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost 2004; 91: 334-344.
• 31 Michelson AD, Barnard MR, Hechtman HB. et al In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 93: 11877-11882.
• 32 Ay C, Dunkler D, Simanek R. et al Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29: 2099-2103.
• 33 Wiesner T, Bugl S, Mayer F. et al Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis 2010; 27: 141-149.
• 34 Salgado R, Benoy I, Bogers J. et al Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis 2001; 04: 37-43.
• 35 Huang Z, Richmond TD, Muntean AG. et al STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. J Clin Invest 2007; 117: 3890-3899.
• 36 Michelson AD, Barnard MR, Krueger LA. et al Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
• 37 Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 2004; 143: 819-826.